Pesquisar
NewAmsterdam Pharma Company NV
NAMSAdicionar à lista de desejos
34.380USD
+0.490+1.45%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.01BValor de mercado
PerdaP/L TTM
Mais detalhes de NewAmsterdam Pharma Company NV Empresa
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Informações de NewAmsterdam Pharma Company NV
Código da empresaNAMS
Nome da EmpresaNewAmsterdam Pharma Company NV
Data de listagemNov 23, 2022
CEODavidson (Michael Harvey)
Número de funcionários68
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 23
EndereçoGooimeer 2-35
CidadeNAARDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1411 DC
Telefone31352062971
Sitehttps://ir.newamsterdampharma.com/
Código da empresaNAMS
Data de listagemNov 23, 2022
CEODavidson (Michael Harvey)
Executivos da empresa NewAmsterdam Pharma Company NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de NewAmsterdam Pharma Company NV?
Os cinco principais acionistas de NewAmsterdam Pharma Company NV são: Mr. John W. Smither
Quantas instituições possuem ações da NewAmsterdam Pharma Company NV (NAMS)?
Em 2026Q1, 366 instituições possuíam ações da NewAmsterdam Pharma Company NV, com valor de mercado aproximado de 128.70M, representando 110.09% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 2432976.00.